Earlier today, Shire plc announced it had received U.S. Food and Drug Administration (FDA) approval for its Xiidra (lifitegrast ophthalmic solution) 5% — a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Xiidra is reportedly the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition. It is dosed twice per day, approximately 12 hours apart, in each eye. Shire reportedly plans to launch Xiidra in the U.S. in the third quarter of 2016.
Click here to read the full press release.